IGF-1 LR3

IGF-1 LR3 (Long R3 IGF-1) is a synthetic analog of human insulin-like growth factor-1 (IGF-1), featuring 83 amino acids with an arginine substitution at position 3 and an additional 13 amino acids at its N-terminus. These modifications reduce binding affinity to IGF-binding proteins by approximately 1000-fold, resulting in enhanced metabolic stability and a significantly longer half-life of 20-30 hours compared to native IGF-1. Research demonstrates that IGF-1 LR3 is 3-6 times more potent than natural IGF-1 in promoting cellular growth and protein synthesis through PI3K/Akt/mTOR signaling pathways. Primary research applications include studies on muscle hypertrophy, satellite cell activation, neurodegenerative diseases, and metabolic regulation. However, IGF-1 LR3 is not FDA-approved for any human therapeutic use and remains classified as a research chemical. It is prohibited by the World Anti-Doping Agency and most professional sports organizations. The compound is available only for laboratory research purposes, with CAS number 946870-92-4.

Muscle Growth and Protein Synthesis

• Enhanced Protein Anabolism: IGF-1 LR3 activates the PI3K/Akt/mTOR pathway, stimulating ribosomal protein S6 and translation initiation factor eIF4E, leading to increased protein synthesis rates in skeletal muscle ^[1][4]
• Satellite Cell Activation: Promotes skeletal muscle regeneration by activating muscle stem cells (satellite cells), contributing to both muscle repair and hypertrophy ^[4][10]
• Reduced Protein Degradation: Suppresses FoxO-mediated transcription of E3 ubiquitin ligases (including MAFbx), preventing muscle protein breakdown through the Akt/mTOR pathway ^[10]
• Superior Potency: Studies demonstrate 3-6 fold greater biological potency compared to native IGF-1 due to reduced IGFBP binding, resulting in enhanced bioavailability ^[12][14]

Metabolic Effects

• Glucose Metabolism: Increases glucose uptake in muscle tissue and reduces hepatic glucose output, demonstrating insulin-like effects on glucose homeostasis ^[11]
• Body Composition: Research in animal models shows maintenance of body weight and nitrogen retention during caloric restriction, though skeletal muscle preservation varies by age and dosing ^[3][8]
• Enhanced Nutrient Delivery: Increases blood flow to skeletal muscle by up to 308% and reduces vascular resistance by 77%, potentially improving nutrient and oxygen delivery ^[13]

Cell Culture and Biotechnology Applications

• Serum-Free Culture: Supports mammalian cell growth at concentrations 200-fold lower than insulin, making it valuable for biopharmaceutical protein production ^[6]
• Stem Cell Research: Effective growth factor for various cell lineages including ectoderm (neurons, oligodendrocytes) and mesoderm (osteocytes, chondrocytes, muscle cells)

Clinical Safety Profile

• Not FDA-Approved: IGF-1 LR3 is not approved by the FDA for any human therapeutic use and is legally available only as a research chemical for laboratory investigations ^[11]
• Limited Human Data: Clinical safety data in humans is extremely limited, with most evidence derived from animal studies and in vitro research
• Prohibited Substance: Banned by the World Anti-Doping Agency (WADA) and professional sports organizations; detected in numerous high-profile doping cases ^[5][11]

Regulatory Status

• Research Chemical Classification: As of January 2023, IGF-1 LR3 is no longer available by prescription due to FDA regulations and remains available only for laboratory research purposes
• Detection Methods: Advanced immunopurification and mass spectrometry methods can detect LR3 IGF-1 in biological samples, though clearance is rapid (within 4 hours post-administration) ^[5]

Side Effects and Adverse Events

• Hypoglycemia: Most common adverse effect; IGF-1 LR3 can significantly lower blood glucose through enhanced peripheral glucose uptake and reduced hepatic glucose production, potentially causing loss of consciousness, seizures, or coma ^[11][15]
• Cardiovascular Effects: Studies show dose-dependent reductions in mean arterial blood pressure (15-25%), potentially causing orthostatic hypotension ^[13]
• Fluid Retention and Edema: Commonly reported in clinical studies, particularly in elderly populations ^[15]
• Other Documented Effects: Headaches, joint and muscle pain (myalgia), jaw pain, nausea, and drug-induced hepatitis in susceptible individuals ^[15]
• Tumor Growth Concerns: Animal studies demonstrate accelerated tumor growth in cancer-bearing rats treated with LR3 IGF-1, raising concerns about mitogenic effects ^[9]

Research Gaps

• Long-term Safety: No long-term human safety studies exist; chronic effects on organ hypertrophy (heart, intestinal tissues) remain unknown
• Optimal Dosing: Therapeutic window and dose-response relationships in humans have not been established
• Age-Related Responses: Limited data on safety profiles across different age groups, with elderly populations showing heightened susceptibility to adverse effects
• Cancer Risk: Insufficient data on long-term cancer risk in humans, though preclinical evidence suggests potential for promoting abnormal cell proliferation